Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

First Posted Date
2023-11-07
Last Posted Date
2024-11-13
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1016
Registration Number
NCT06119581
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

🇦🇹

Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria

and more 361 locations

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

First Posted Date
2023-10-31
Last Posted Date
2023-12-19
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
160
Registration Number
NCT06109402
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

First Posted Date
2023-10-24
Last Posted Date
2024-12-13
Lead Sponsor
AstraZeneca
Target Recruit Count
600
Registration Number
NCT06097728
Locations
🇬🇧

Research Site, Taunton, United Kingdom

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

First Posted Date
2023-10-24
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
304
Registration Number
NCT06096844
Locations
🇺🇸

Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States

🇺🇸

Highlands Oncology Group - Rogers, Rogers, Arkansas, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

and more 219 locations

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

First Posted Date
2023-10-23
Last Posted Date
2024-06-26
Lead Sponsor
AbbVie
Registration Number
NCT06093503

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

First Posted Date
2023-10-23
Last Posted Date
2024-10-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1
Registration Number
NCT06094296
Locations
🇺🇸

Local Institution - 0058, Boise, Idaho, United States

🇺🇸

Local Institution - 0044, Clermont, Florida, United States

🇺🇸

Local Institution - 0049, Houston, Texas, United States

and more 5 locations

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

First Posted Date
2023-10-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
556
Registration Number
NCT06074588
Locations
🇧🇷

A. C. Camargo Cancer Center-CAPEC ( Site 0442), Sao Paulo, Brazil

🇧🇷

Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0446), Sao Paulo, Brazil

🇨🇱

K2 Oncology ( Site 0514), Santiago, Region M. De Santiago, Chile

and more 165 locations

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

First Posted Date
2023-09-28
Last Posted Date
2024-10-28
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
64
Registration Number
NCT06057935
Locations
🇺🇸

University of Chicago (Data Collection Only), Chicago, Illinois, United States

🇺🇸

University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States

🇺🇸

University of Nebraska (Data collection only), Omaha, Nebraska, United States

and more 10 locations

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

First Posted Date
2023-08-23
Last Posted Date
2024-12-11
Lead Sponsor
AstraZeneca
Target Recruit Count
280
Registration Number
NCT06008093
Locations
🇺🇸

Research Site, Milwaukee, Wisconsin, United States

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

First Posted Date
2023-08-21
Last Posted Date
2023-08-21
Lead Sponsor
Qian Chu
Target Recruit Count
49
Registration Number
NCT06001151
Locations
🇨🇳

Qian Chu, Wuhan, Hubei, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy